Compare Diageo plc (DEO) vs Novavax Inc (NVAX) Price & Performance

Diageo (DEO) trades at $84.73, down 0.06% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027. The balance sheet shows $2.65B in cash against $23.75B in total debt, with a debt-to-asset ratio improving to 48.05% in 2026.

The outlook is mixed: analyst consensus leans bullish (49% buy ratings) with a focus on the US turnaround plan, but 2026 projections show declining revenue and net income. Key risks include execution of the restructuring, competitive pressures, and regulatory challenges in markets like India. The stock offers income via dividends but faces near-term fundamental headwinds.

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.